Allogene Therapeutics (NASDAQ:ALLO) Receives “Buy” Rating from HC Wainwright
HC Wainwright reissued their buy rating on shares of Allogene Therapeutics (NASDAQ:ALLO – Free Report) in a report published on Thursday, Benzinga reports. HC Wainwright currently has a $9.00 price target on the stock. Other equities analysts also recently issued research reports about the stock. Piper Sandler initiated coverage on shares of Allogene Therapeutics in […]
More Stories
A Man on the Inside: Release Date, Trailer, Plot, and Episode Updates
Is your favourite detective, Ted Danson, returning with a season 3 of A Man on the Inside? Fans are looking...
8 Killed After Charter Plane Crashes in Western Alaska: US Military
By AldgraFredly The U.S. military said on Aug. 20 that eight people were killed after a charter plane crashed at...
Israel, Turkey Continue Dispute Over Syria After Airbase Strike
By Evgenia Filimianova Israel and Turkey have deepened their dispute over Syria after Israel defended its strike on a Syrian...
First Lady Unveils Racing Collaboration, $2 Million in ‘Fostering the Future’ Scholarships
By Travis Gillmore WASHINGTON—First Lady Melania Trump held her first public event in about two months at the White House...
US Unemployment Claims Unexpectedly Dropped Last Week
By Andrew Moran The number of Americans submitting applications for unemployment benefits unexpectedly declined last week for the first time...
A Tale of 2 Straits: Global Shippers Prefer Washington’s Version Over Tehran’s
By John Haughey With the Aug. 17 expiration of the 60-day memorandum of understanding between the United States and Iran,...